Latest news

• Novo Nordisk's Tresiba gaining ground in basal insulin market

  Novo Nordisk's Tresiba gaining ground in basal insulin market. Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus. ... Nevertheless, the strong sales performance for Tresiba and other new insulin

• Tresiba safer than insulin glargine, says Novo Nordisk

  Tresiba safer than insulin glargine, says Novo Nordisk. Trial compares its basal insulin with Sanofi's Lantus. ... Last October however the Danish drugmaker finally won US approval for Tresiba and combination product Ryzodeg (insulin degludec and insulin

• Novo Nordisk finally bags insulin degludec approval in US

  Novo Nordisk finally bags insulin degludec approval in US. Aims to get Tresiba and Ryzodeg back on course . ... Long-acting basal insulin Tresiba (insulin degludec) and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able to

• Novo brings Xultophy to third European market

  Novo Nordisk has launched its diabetes drug Xultophy (insulin degludec and liraglutide) in the UK, following its arrival earlier this year in Germany and Switzerland. ... US regulators dealt the company a major blow in February 2013 when marketing

• FDA starts review of Novo's refiled diabetes pair

  The US FDA has started a fresh review of Novo Nordisk's long-acting insulin therapies Tresiba and Ryzodeg, which it turned down two years ago. ... Tresiba (insulin degludec) and combination product Ryzodeg (insulin degludec and insulin aspart) were